IDEAYA Biosciences Inc (NAS:IDYA)
$ 36.63 -1.08 (-2.86%) Market Cap: 2.77 Bil Enterprise Value: 2.16 Bil PE Ratio: 0 PB Ratio: 2.93 GF Score: 37/100

IDEAYA Biosciences Inc at Stifel Healthcare Conference Transcript

Nov 16, 2022 / 01:00PM GMT
Release Date Price: $17.74 (-0.17%)
Paul Stone
IDEAYA Biosciences, Inc. - SVP & CFO

Yes, Ben, thanks for having us, and thanks to Stifel, for hosting us at the conference.

Ben Burnett
Stifel Financial Corp. - Analyst

To start off, maybe just give a brief overview of IDEAYA, and maybe talk about your approach with synthetic lethality, just highlight near-term events that we should be paying attention to.

Paul Stone
IDEAYA Biosciences, Inc. - SVP & CFO

Yes, IDEAYA is a precision medicine oncology company with a research and development focus in synthetic lethality. Our approach to synthetic lethality is straightforward. We are focused on identifying, then executing on targets that have the potential to be first-in-class. And we think therefore the most potentially impactful for patients.

We have currently two programs that are in clinical trials, our Phase 2 Darovasertib and our early Phase 2 IDE397 targeting MAT2A. But as we look forward over the next few quarters, we will have four programs in the clinic is what we're guiding

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot